Mark A. Socinski, MD, AdventHealth Cancer Institute

Frontline I-O Monotherapy Versus Combination Therapy for PD-L1+ Stage IV NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

June 30th 2021

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

Frontline Treatment of PD-L1+ Stage IV NSCLC: Cemiplimab

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

June 30th 2021

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.

Future Directions in Biomarker-Based Oncology

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

May 12th 2021

Experts in oncology discuss future directions in biomarker-driven therapy.

Tumor Agnostic RET Inhibition: The ARROW Trial

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

May 5th 2021

Dr Jyoti Patel presents data from the ARROW clinical trial.

RET as a Therapeutic Target for Solid Tumors

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center

April 28th 2021

Expert oncologists discuss RET-driven therapy for select solid tumors.

TRK Fusion Inhibitors in Clinical Practice

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan C. Trent, MD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 28th 2021

Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.

TRK Fusion Inhibitors in Tumor-Agnostic Clinical Trials

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 21st 2021

Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.